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Each year more than 10,000 West Virginians are newly diagnosed with cancer (Hudson, 
2011).  There is an interest among policymakers, care providers, industry officials, and others to 
reduce the impact of cancer in the state. Several key objectives aimed at prevention, early 
detection, and quality of life are outlined in the West Virginia Cancer Plan, including the 
objective to increase enrollment in cancer trials (Mountains of Hope, 2007).  In addition, there is 
a significant opportunity to impact the lives of cancer patients and their families, as well as the 
West Virginia economy, by altering cancer care options in the state. 
About one in five newly diagnosed West Virginia cancer patients elect to receive their 
cancer care in another state.
1
  Enhancing the existing cancer care system in West Virginia might 
induce more patients to receive their care in-state, reducing the travel burden on families.  
Implementing and operating a West Virginia cancer clinical trials network would create new 
opportunities for patients and generate a significant economic impact in West Virginia.  We 
estimate that about $360 million is spent in other states for the cancer care of West Virginia 
residents.  This spending results in just under 3,000 outside jobs.  Accounting for the indirect 
effects of medical spending on retail sales and the broader economy, we estimate that about $622 
million in economic activity spills into neighboring states for the care of West Virginia cancer 
patients. 
                                                          
1
 Based on tabulations from the West Virginia Cancer Registry of patients diagnosed in 2008 that received some 
type of cancer care in another state.  In our analysis, each patient is categorized as either in-state or out-of-state for 
the purposes of our calculations and we use 20% receiving out-of-state treatment as the basis for the out-of-state 
group.  Note, that if some of these patients receive a portion of their care in West Virginia, we might overstate the 
amount of spillover.  Likewise, if some of the in-state patients opt for out-of-state treatment at some point in the 
future, or if those going out-of-state for some cancer care receive additional medical services note related to cancer 
care, we have understated spillovers.  Estimates of the economic impact of the cancer clinical trials network are 
based on the conservative assumption that the trial network only retains 20-50% (depending on year of operation) of 
the patients going out-of-state for cancer trials and we assume a 5.8% participation rate for trials.  This assumption is 
less impacted, since the availability of clinical trials presents options for patients to be treated in West Virginia 
regardless if they are on trial.  Thus, the impacts of the cancer clinical trials network are based on retaining 0.2 to 
0.6% of newly diagnosed patients. 
 4 
Nationally, only about 5 percent of newly diagnosed cancer patients participate in cancer 
clinical trials, but retaining just a fraction of these patients in West Virginia would generate 
millions in economic activity and hundreds of new jobs.  The trial network is estimated to 
generate $11 million in new economic activity and 90 jobs in its first year, and impacts are 
expected grow to over $36 million and 300 jobs by its sixth year.   
The economic effects of a new trial network are divided into two main areas. First, funds 
to operate the network and research grants would come from federal and industry sources, 
representing new spending in the state.  Second, the trial network would provide an incentive for 
West Virginians to remain in the state to participate in a trial and to receive other cancer care.  
The sizable gains to the West Virginia economy and West Virginia families are mainly 
attributable to the second source. 
Operating expenses and grant revenues account for about 14 percent of the total 
economic impact.  In the first year, operating expenses of $762,000 and grants of $76,000 result 
in $1.486 million in direct and indirect economic activity, generate 12 jobs, and add state tax 
revenues of about $30,000. In the sixth year, as the network becomes more established, operating 
expenses and grant revenues increase to about $3 million and total economic impacts increase to 
$5.3 million, 44 jobs are created, and state tax revenues would increase by about $100,000. 
Although operation of the trial network results in significant economic activity, the 
largest gains are possible by retaining West Virginia cancer patients in the state for care, 
particularly in the first year of treatment.  Retaining 20 percent of cancer trial participants in-
state for care would increase economic activity in the state by almost $10 million.  Retaining 50 
percent of trial participants by the sixth year of the trial network would increase economic 




in the first year and 303 jobs by the sixth year at an average wage of just under $47,000.  Tax 
revenues increase by $200,000 in the first year and by more than $670,000 in the sixth year.  
These numbers do not include harder-to-quantify effects on quality of life as West 
Virginians would have the opportunity to remain in-state for trials and develop stronger 
relationships with local care professionals.  The research also highlights the vast opportunity to 
increase economic activity by providing more in-state cancer care for residents.  The above 
estimates assume that a cancer trial network retains 20 to 50 percent of cancer trial participants 
in-state for their cancer care.  These patients account for only a small portion of cancer patients 
who leave the state for care, and efforts to retain more patients in-state for quality cancer care 
would lead to substantial activity in the West Virginia economy. 
 6 
Introduction 
 In 2008, about 20 percent of West Virginians newly diagnosed with cancer received their 
cancer care at an out-of-state facility.  Some of this out migration might be due to the lack of a 
cancer trial network in the state of West Virginia.  The presence of a trial network might not only 
induce patients to remain in the state for cancer trial participation, but to also receive their cancer 
care in West Virginia.  This report is divided into several sections aimed at providing a general 
sense for the economic activity associated with implementing a new cancer trial network and 
potential economic gains if more West Virginia cancer patients opted to receive their cancer care 
in-state because they could participate in a trial.  We estimate the direct economic effects from 
operating expenses, research grants, and medical and travel expenses.  In addition to direct 
expenditures, we estimate the indirect effects on the economy in terms of business volume (e.g. 
increased retail sales), total jobs, and state tax revenue.   
Initially, we include only the expected cancer trial network operating expenditures and 
additional research grant funding that is possible with researcher access to a trial network.
2
   We 
estimate direct expenditures to be $838,000 in the first year, including about $762,000 in 
operating expenditures and $76,000 in external grant funding.  These expenditures result in about 
$648,000 in indirect economic activity for a total first-year impact of $1.486 million. By year 
six, direct expenses and grant revenues are expected to increase to $3.003 million generating a 
total economic impact of $5.327 million.  We estimate that the cancer trial network would 
generate 12 total jobs in the first year and that this number increases to 44 jobs by the sixth year.  
Based on these figures, the state would see about $30,000 in increased tax revenue in the first 
year and $100,000 in the sixth year. 
                                                          
2
 Note that the grant revenue may accrue to the cancer trial network directly or to other entities within the state 




These economic impacts increase by more than a factor of ten if the presence of an in-
state trial network induces a portion of trial participants to remain in West Virginia for their 
cancer care.  In 2008, about 20 percent of newly diagnosed cancer patients received care outside 
of the state.
3
  Of these patients, we would expect about 5.8 percent to participate in a cancer 
trial.
4
    We assume that one in five trial participants will remain in state for care in the first year 
of trial network operation and that this number will steadily increase to one half of trial 
participants by year five and remain at 50 percent going forward.  We also allow for the 
possibility that a small number of out-of-state cancer patients will be drawn to West Virginia for 
cancer care because of the presence of the new cancer trial network.   
Adding in the economic gains from retaining more patients in-state for care, we estimate 
that a new cancer trial network will result in $11.2 million in economic activity in the first year.  
By the sixth year of operation, we estimate that the impact will grow to $36.8 million.  The new 
trial network is expected to generate about 90 jobs in the first year and 300 jobs by the sixth year. 
In the sections below, we outline our main assumptions and present the economic impact 
estimates.  In the following section, we estimate the total amount of economic activity that 
occurs in other states due to the out-migration of West Virginia residents for cancer care.  Next, 
we estimate the economic impacts of implementing and operating a new cancer clinical trials 
network in West Virginia.  We begin by estimating the impact running the trial network 
(operating expenditures and grant revenues), which represents new economic activity to the state 
as funding will come from federal and industry sources.  We then estimate the economic impact 
of retaining a portion of West Virginia cancer clinical trial participants in-state for their cancer 
                                                          
3
 Based on tabulations from the West Virginia Cancer Registry. 
4
 This estimate is based on a survey of West Virginians with new cancer diagnoses in 2009 and allowing for higher 
trial participation rates among patients with female breast cancer (12 percent) (Health Statistics Center, 2010).  This 
estimate is likely to be a lower bound as the possibility of trial networks in other states likely lead a higher 
percentage of trial participants to seek care outside of the state than those not participating in a trial. 
 8 
care. In the final section we present conclusions. Detailed information on data sources and 




Economic Impact of Out-of-State Care for Patients who were Newly 
Diagnosed in 2008 
Estimates in this section are meant to provide a reference point for the estimated annual 
economic activity that spills over into other states when West Virginia cancer patients receive 
care at out-of-state facilities.  These estimates represent the amount of spillover in one year 
(2008) for lifetime expected cancer-related care and the difference in in-state and out-of-state 
travel expenses.  Given the recent trends in medical and travel costs, we would expect the dollar 
amount of these impacts to increase over time. 
In 2008, just under 2,100 patients or about 20 percent of West Virginians newly 
diagnosed with cancer received their cancer care in another state.
5
  We estimate the amount of 
economic activity associated with their out-of-state care and travel expenses.  The two main 
components of these estimates are direct expenses (medical and travel), and indirect effects (e.g. 
retail sales, employment in other sectors).  We calculate lifetime expected medical expenses as 
the sum of first year, continuing year, and final year treatment.  Costs are calculated for seven 
different cancer sites (colorectal, female breast, leukemia, lung and bronchus, non-Hodgkin 
lymphoma, prostate, and liver) as well as an “other” category.  We then assign 20.2 percent of 
total medical expenses to an out-of-state category based on the percentage of patients diagnosed 
in 2008 that received care in another state resulting in an estimate of $309 million.
6
  Accounting 
for indirect effects, we estimate that the total cost to West Virginia from patients going out-of-
state in 2008 is $539 million. 
 We approach travel slightly differently.  If medical care received out-of-state were 
provided in West Virginia, this would represent new economic activity to the state.  In the case 
                                                          
5
 Based on tabulations from the West Virginia Cancer Registry. 
6
 See Appendix A for detailed information on our data sources and calculations. 
 10 
of travel, patients will make some travel expenditures for care whether it is in West Virginia or 
outside of the state.  In this case, we take the difference in mean in-state and meant out-of-state 
travel costs and multiply by the number of patients receiving care outside of the state (2,071).  
By staying in-state for treatment, the difference in travel costs is now available for household 
consumption and will result in added economic activity.
7
  We estimate additional travel expenses 
to be about $7.9 million for patients receiving care out of the state.
8
   
Next, we run these estimates through the IMPLAN
®
 model (allocated to the medical and 
travel industries as appropriate) to estimate the amount of indirect economic activity associated 
with out-of-state care spending.  We estimate that medical care and travel costs amount to almost 
$360 million for patients newly diagnosed in 2008 (Table 1).  Medical expenditures account for 
almost 98 percent of this total or about $349 million.  Travel expenditures contribute about $8 
million in direct expenditures.  As shown in Table 1, we estimate that these direct expenditures 
generate over 2,900 jobs.  This spending has an indirect effect on the economy, as employees 
live and shop in the local economy.  We estimate that the total economic impact, direct and 
indirect, is about $622 million and generates a total of 5,100 jobs.  It is perhaps unrealistic to 
think that all of this activity could be retained in West Virginia, but keeping just a portion of 
these patients in West Virginia for cancer care produces significant economic impacts as outlined 
in the following section. 
                                                          
7
 Note that with this approach we implicitly assume that some travel expenditures (e.g. gasoline) are made in West 
Virginia even if the patient is receiving out-of-state care. 
8
 Travel estimates are based on an assumption that 25 trips will be made in the first year of care.  We do not include 
travel expenses for future years, assuming that continuing care can be scheduled to coincide with other routine 




Table 1: Total Economic Impact of Cancer Care Out-Migration from  
West Virginia (Millions of 2008 Dollars) 
  Direct 
Indirect & 
Induced Total 
Total Cancer-related Economic Activity ($millions) $357 $264 $622 
Employee Compensation ($millions) $175 $63 $238 
Employment (jobs) 2,935 2,167 5,101 
 
 12 
Potential Cancer Trial Network Economic Impacts (2011-2016)9 
 A portion of newly diagnosed cancer patients and those living with cancer beyond the 
year of diagnosis are eligible to participate in cancer trials.  The absence of a cancer trial network 
in the state of West Virginia means that many of these patients will seek treatment outside of the 
state or forgo trial participation.  In this section, we estimate the additional economic activity that 
the state would accrue with the implementation of a cancer trial network. 
Key Assumptions 
 There are two key components to our estimations: economic impacts due to operating the 
cancer trial network and economic impacts from retaining more West Virginia residents in-state 
for trial participation and cancer care.  The first component includes cancer trial network 
operating expenses and grant revenues accumulating for medical research to trial network 
providers and other researchers in the state.  Operating expenses are funds that are new to the 
state (from federal or corporate sources) and generate new economic activity and tax revenue 
when expended on items such as salaries and equipment.
10
  Grant revenue represents an estimate 
of the additional funds that West Virginia researchers are able to procure due to the presence of 
an active trial network.  The second component includes medical and travel expenses associated 
with cancer care.  Medical expenses represent funds that are newly spent in West Virginia as 
patients choose to receive care in West Virginia because of the presence of the cancer trial 
network.  Travel expenses represent the difference in mean in-state and out-of-state travel 
expenses that are newly available for household consumption when a patient receives care in 
West Virginia because of the presence of the cancer trial network.   
                                                          
9
 Please see Appendix A for a list of data elements and sources as well as underlying calculations. 
10
 We distinguish between funding from external sources and state funding, which would represent a transfer from 




A few key assumptions are worth noting as they are important for determining what 
expenses are counted in our estimates.  First, implementation of a new trial network might 
induce patients to participate in trials that they would not have considered if faced with traveling 
out-of-state.  We do not include these patients in our economic impact numbers because it is 
unlikely that they were leaving the state for treatment prior to implementation of the cancer trial 
network.  
Second, after talking with experts in the field, there is not a preponderance of evidence to 
suggest that trial participation clearly affects expected longevity or non-trial medical expenses.  
To the extent that those who participate in trials have better health outcomes or receive some of 
their routine cancer care through the trial, our estimates will understate the actual economic 
impact of a new cancer trial network. 
Finally, we calculate the expected trial participation rate using the 5 percent rate reported 
in Health Statistics Center (2010) for West Virginia and adjusting this number for higher rates of 
participation among those with a breast cancer diagnosis (12 percent).  We arrive at a weighted 
mean participation rate of 5.8 percent, which is used in the medical and travel calculations that 
will follow. 
Operating Expenses 
 Budget planning for the potential cancer trial network calls for funding from federal and 
industry sources.  These funds would represent new spending in the state and would generate 
additional economic activity, jobs, and tax revenue.  We take a conservative approach to 
including budget numbers in our economic estimates; we include only expected expenditures, 
not total revenue or margin distributions (when applicable).  Only direct expenditures are 
included because these are the most likely to be funneled into the West Virginia economy.  
 14 
Retained revenue or distributions might not have an immediate impact on the economy or might 
be invested/spent outside of the state.  Estimated operating expenses are about $762,000 in 2011 
and steadily increase to just over $2 million in 2016, as illustrated in Figure 1 (West Virginia 
Clinical Trial Network Draft Operating Statement, 2012). 
Figure 1: Estimated Cancer Trial Network Operating Expenditures 
 
Grant Revenue 
 The presence of an in-state cancer trial network will improve the chances that West 
Virginia cancer researchers are successful in securing external research funding.
11
  We assume 
that researchers will generate revenues equal to about 10 percent of the cancer center operating 
budget in the first year.  In the second year, we assume that researchers will generate revenues 
equal to about 20 percent of the cancer center operating budget, which will increase to 50 percent 
of the budget by year 5 (whether the researchers are serving as PI or have other roles on grant 
applications).  Based on these assumptions, expected grant revenues range from $76,000 in the 
first year to $1 million in year 6 (Figure 2). 
                                                          
11

















Figure 2: Estimated Trial Network-related Grant Revenue 
 
Medical Expenses 
 Medical expenses are estimated for two main groups, those newly diagnosed in 2011 
(10,770) and those currently living with cancer post-diagnosis (86,161) (2011 Claritas 
Population and SEER incidence rates).  For new diagnoses, we include first-year continuing care 
costs in our estimates and for those living with cancer post-diagnoses we include only expected 
costs for the ‘continuing’ years, those between the first year of diagnosis and the year of death.  
Due to the nature of cancer treatment, the majority of treatment costs are borne in the first year 
so that retaining a newly diagnosed patient in the state for care has a larger economic impact than 
recruiting a patient beyond the first year of treatment.  However, a limitation of our analysis is 
that we do not estimate the harder-to-quantify aspects of cancer treatment that affect quality-of-
life, which could be significantly enhanced for an existing patient who can remain in-state for 
“continuing” treatments. 
















                  ∑                                             
   
   
 
Where T is the number of years from diagnosis to death and i represents an individual, and j 
represents cancer site.  We calculate costs for seven different cancer sites (colorectal, female 
breast, leukemia, lung and bronchus, non-Hodgkin lymphoma, prostate, and liver) as well as an 
“other” category.  Cost of care estimates are taken from the National Cancer Institute, Average 
Annual Costs of Care (2011).
12
  The number of years of continuing care is calculated by cancer 
site as the difference between average age of death and average age of diagnosis.
13
  Our 
estimates range from an average lifetime cost (in 2011 dollars) for treating female breast cancer 
of $118,904 to an average cost of $228,891 for leukemia.  We multiply the average cost of care 
for each cancer site times the number of newly diagnosed cases that received treatment out-of-
state.  Our total estimate (in 2011) dollars of the lifetime cost of cancer care for new diagnoses in 
2011 that receive treatment out-of-state is $374 million.  Continuing care costs for the more than 
80,000 patients living with cancer post–diagnosis are estimated to be another $359 million. 
 Among patients leaving the state for care, we expect about 5.8 percent (assuming a 12 
percent participation rate for breast cancer patients and 5 percent for all other cancer sites) to be 
participating in cancer trials.  To calculate medical expenses for trial participants newly 
diagnosed with cancer we calculate medical expenses as total expected out-of-state medical 
expenditures for 2011 times the cancer trial participation rate to get $22 million.  For those living 
with cancer post-diagnosis, we take the expected medical costs of trial participants for continuing 
years (the portion of total expected lifetime medical costs that is attributable to the years between 
                                                          
12
 Estimates are provided in 2010 dollars, which we adjust back to 2008 dollars to match our cancer data. 
13
 We calculated a weighted average age of diagnosis and death (the sum of the percent in each age category times 
the median age in each category; e.g. about 2 percent of colorectal cancer diagnoses occur at between the ages of 45 




diagnosis and death) of those diagnosed in 2011 and multiply by the ratio of eligible existing 
cases to new cases (0.96).  The ratio is calculated as the number of existing cases (86,161) times 
the percent eligible for treatment (30 percent) times the percent eligible for trial participation (40 
percent), resulting in 10,339 cases (Oncology Solutions, 2012) divided by 10,770 newly 
diagnosed cases.
14
  Our estimate of medical expenses for continuing cases is $4 million. 
 The presence of a cancer trial network in West Virginia might also induce new economic 
activity as patients in neighboring states choose to receive care in West Virginia because of the 
presence of the cancer trial network.  To account for this possibility, we estimate the dollar 
amount of potential medical expenditures from out-of-state residents.  We first calculate the 
relative size of the population living in West Virginia’s bordering counties
15
.  Based on Census 
data, border county population totals 2.154 million.  This is 1.161 times greater than West 
Virginia’s population of 1.855 million.  We take the estimated number of cancer cases in the 
border counties and estimate the number of cases that might seek cancer trial participation and 
treatment out-of-state based on West Virginia’s out-of-state treatment rate and trial participation 
rates.  Finally, we assign our estimated average cost of care to these potential patients.  In sum, 
we estimate that potential out-of-state participants could generate economic activity that 
represents about 7 percent of that generated by in-state patients (about $2 million for newly 
diagnosed and continuing patients). 
 For the first year of the trial network, we assume that an in-state cancer trial network 
would induce 20 percent of patients in cancer trials to stay in-state for trial participation and 
medical treatment.  This results in about $5.571 million in additional medical spending in the 
state.  This breaks down into $4.330 million for newly diagnosed patients, $874 thousand for 
                                                          
14
 Note that we assume that only 5.8 percent of these cases will actually participate in a trial. 
15




 and $367 thousand for new and previously diagnosed out-of-state patients.  
We expect the portion of trial patients remaining in-state to increase as the trial network becomes 
established.  In year 2, we assume that 20 percent of trial participants will stay in-state for their 
trial and treatment.  We increase the portion remaining in-state by ten percentage points a year to 
a maximum of 50 percent in years 5 and 6.  This assumption recognizes that an in-state trial 
network might not be able to serve all trial participants, particularly those diagnosed with rare 
cancers.   
Travel Expenses 
 Travel expenses are estimated as the difference in mean in-state travel costs and mean 
out-of-state travel costs for trial participants.  Thus, in-state trial participation and cancer care 
does not eliminate travel costs, but reduces them, freeing up the difference for household 
consumption.  We calculate travel savings only for West Virginia residents newly diagnosed 
with cancer, implicitly assuming that any costs or savings that accrue to out-of-state patients will 
likely benefit their local economies.
17
 
To calculate travel costs, we assume that the patient will make 25 trips for cancer 
treatment in the first year of treatment.  The number of trips is calculated as the average number 
of trips indicated in treatment protocols for breast cancer, colorectal cancer, lung cancer and 
leukemia.  We also assume that a working-age adult will accompany the patient.  Out-of-state 
travel expenditures are calculated based on county of residence.  For each county, we collect the 
distance from the county seat to the nearest major out-of-state cancer treatment center.   The 
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 Note the lower total for continuing cases, largely due to the difference in first-year and continuing year treatment 
costs. 
17
 We do not include travel expenses for trial participants beyond the first year of treatment as these trips are harder 
to quantify.  As such, the travel estimates should be viewed as conservative, but this does not have significant 





average round trip for out-of-state treatment is 136 miles.  The cost of each trip is calculated as 
the roundtrip mileage times the medical travel reimbursement rate ($0.23)
18
 plus one night of 
lodging at the General Services Administration (GSA) reimbursement rate for the treatment 
location.  The mean lodge rate is $112 across all out-of-state locations.  We also assume that the 
patient and the accompanying adult forego two days of work at the mean daily wage rate for the 
county (mean daily wage is $91 across all counties).  For those receiving treatment in West 
Virginia, we assume that the average in-state round trip is 50 miles, the patient and 
accompanying adult forego one day of wages at the mean daily wage rate for the county, and 
there is no expenditure for lodging.
19
   
 In our first year scenario where 20 percent of cancer trial patients are retained in-state, we 
estimate the travel savings for patients remaining in-state for trials and care to be about 
$396,000.  By year six, travel savings are expected to be about $1.285 million as more patients 
elect to stay in West Virginia for trials and cancer care.  Although it is clear that travel savings 
result in economic gains, they are much smaller in magnitude than the potential gains from 
retaining patients for in-state cancer treatment as illustrated in Figure 3. 
                                                          
18
 This is the average medical reimbursement rate for 2008.  Note that the medical reimbursement rate is lower than 
the average business travel reimbursement rate of $0.545 in 2008.  We utilize the more conservative medical rate in 
our calculations. 
19
 We calculated the distance from each county seat to the nearest in-state hospital.  The mean distance for all 
counties is 35 miles each way for a round trip of 70 miles.  Because population is greater in more urban areas with 
hospitals, we chose a more conservative estimate of 50 miles round trip for our analysis. 
 20 
Figure 3: Relative size of Medical and Travel Expenses in First Year Estimates 
 
Total Economic Impacts 2011-2016 
 In this section we estimate the total economic impacts of implementing a caner trial 
network in West Virginia.  In addition to the direct operating, grant, medical and travel effects 
discussed above, we estimate the indirect economic effects using the West Virginia IMPLAN
®
 
model.  We input operating expenditures, grants, and medical spending into the medical sector, 
and travel spending into the travel sector (excluding recreation and entertainment).  Indirect 
effects include economic activity such as retail sales and tax revenues that are associated with the 
households and jobs created by the increased spending in each sector. 
 First, we consider just the economic activity associated with operating the cancer trial 
network and grant research.  These estimates represent the economic impact of the new trial 
network in the absence of any changes in patient care behavior.  That is, these are the economic 
effects assuming that none of the current out-of-state trial participants are induced to receive 
their cancer care in West Virginia.  As shown in Table 2, operating expenditures grow from 








established and robust.  Expected grant revenues also increase from $76,000 to just over $1 
million as the network becomes more established and researchers are able to capitalize on the 
opportunities.  Our estimates for total economic activity include direct and indirect effects.  We 
expect the trial network operation to increase economic activity in West Virginia by about $1.5 
million and create 12 jobs in year 1.  By year six, we expect the network to increase economic 
activity by over $5 million, create 44 jobs, and increase state tax revenue by about $100,000.   
Table 2: Economic Impacts of Trial Network Operating Expenses and Research Grants 
 
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 
Operating Expenses ($) 761,615 844,158 912,550 1,870,873 1,913,211 2,002,013 
Research Grants ($) 76,162 168,832 273,765 748,349 956,606 1,001,007 
Total Economic Activity ($) 1,486,108 1,796,914 2,104,371 4,646,164 5,090,686 5,326,971 
Jobs 12 15 17 38 42 44 
Tax Revenue ($) 27,889 33,722 39,492 87,192 95,534 99,968 
 
Figure 4 illustrates the relative importance of each of the components in generating the 
total economic impact estimate.  Just over half of the impact is from direct operating 
expenditures (e.g. salary payments and supplies).  It is apparent from Figure 4 that accounting for 
the substantial indirect effects is important for getting a complete picture of the economic effects.   
 22 
Figure 4: Relative size of Operating, Grant and Indirect Effects in the First Year 
 
 
 The economic impacts of a cancer trial network are more than seven times larger if the 
network retains more West Virginians in the state for trial participation and cancer care, 
particularly cancer care in the first year following diagnosis.  Table 3 presents economic impacts 
for retaining 20 to 50 percent of trial participants in-state for cancer care over the first six years 
of the clinical trial network.  Medical expenses are estimated to grow at 2 percent annually.  This 
conservative growth projection is chosen given the uncertainty over future health care spending 
with the implementation of the Affordable Care Act.  Travel costs are also assumed to grow by 2 
percent annually.  Research grants are 10 percent of operating expenditures in the first year, 20 
percent in the second year, 30 percent in the third year, 40 percent in the fourth year, and 50 
percent thereafter.  Expected operating expenditures are taken from Oncology Solutions (2012). 
Total economic activity is expected to increase by more than $11 million and 92 jobs in year 1.  
The economic impact is expected to grow to almost $37 million and 303 jobs in year 6.  State tax 










Table 3: Total Economic Impacts of a West Virginia Cancer Trial Network 
 
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 
Medical ($) 5,570,512 5,681,922 8,693,341 13,909,346 17,734,416 18,089,104 
Travel ($) 395,655 403,568 617,459 1,234,918 1,259,617 1,284,809 
Operating ($) 761,615 844,158 912,550 1,870,873 1,913,211 2,002,013 
Research Grants ($) 76,162 168,832 273,765 748,349 956,606 1,001,007 
Total Economic Activity ($) 11,195,084 11,679,709 17,271,761 29,227,715 35,974,377 36,818,595 
Jobs 92 96 142 240 296 303 
Tax Revenue ($) 204,087 212,922 314,865 532,823 655,815 671,205 
 
 Figure 5 illustrates the relative importance of each of the factors in the overall economic 
impact.  Half of the total arises from increased spending for medical care in West Virginia.  
Thus, recruiting and retaining West Virginians in-state for cancer trials and cancer care will 
largely determine the ultimate economic impact of a cancer trial network in West Virginia.  
Indirect effects make up the next largest category (39 percent), illustrating the importance of 
accounting for indirect effects when estimating the economic impact.  Operating expenditures 
represent 7 percent of the total and travel savings account for 3 percent.  Although travel savings 
are not a major component of the overall impact, these savings could have an important impact 
on the well-being of West Virginia families.  Grant revenues account for 1 percent of the total 
economic impact, but this category is likely to be of great importance in recruiting and retaining 
the top cancer doctors and care providers. 
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Figure 5: Relative Size of Operating, Grant, Medical,  
















 An in-state cancer trial network would have a clear economic impact on the West 
Virginia economy.  However, the ultimate size of the effect depends crucially on how many trial 
patients who would have received their care in another state opt to receive cancer care in West 
Virginia because of the trial network.  We estimate that the trial network would increase 
economic activity in the state by more than $11 million in the first year and by nearly $38 
million in the sixth year.  About half of this impact is from increased medical spending on cancer 
care and more West Virginia patients remain in the state for care, particularly in the year 
following their diagnosis. 
Of course, there are a number of factors associated with a new trial network that do not 
lend themselves to quantification.  Included in this category are the psychological and quality-of-
life effects of trial participation for the patient and his or her family.  Some of these factors might 
have economic consequences (e.g. stress causes health problems that require medical care or 
missed days from work) and others might not have a clear impact on economic activity, but 
could seriously affect the lives of patients, their families, and caregivers.  In fact, the West 
Virginia Cancer Plan identifies increasing cancer trial participation as a key objective for 
improving quality of life (Mountains of Hope, 2007).  Because we are not able to quantify all of 
these effects, we view the economic impacts presented above as a lower bound estimate of the 
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Appendix A: Data and Calculations 
Data Elements 
NAME OF THE 
VARIABLE 
 
DESCRIPTION SOURCE OF DATA 
LIST OF MAIN 
AREAS WHERE THE 
DATA IS USED 
Shortest travel 
distance in miles 
Distance from the county seat to 
the nearest out of state hospital 
Google maps shortest distance 
calculator 
Used to calculate 
mileage cost for out of 
state travel expense 
 
Mileage rate Standard mileage rate at IRS for 




Used to calculate 
mileage cost for 
instate and out of 
state travel expense 
 
Lodging rate Maximum rate for one night stay 





Used to calculate 
lodging cost for both 
out of state and 
instate travel expense 
 
Out of state 
treatment cases 
by county 
The number of out of state 
cancer cases by county in WV in 
2008 
Tabulations provided by 
the West Virginia Cancer 
Registry and researchers at the 
Mary Babb Randolph Cancer 
Center
Used to calculate the 
number of instate 
cancer cases, mileage 
lodging and forgone 
wage cost for out of 
state travel expense 
Total cases of 
cancer 
The total number of cancer cases 
by county in 2008 in WV 
West Virginia Cancer Registry 





Used to calculate the 
instate cancer cases, 
weighted average 
wage per week and 
per year and total 






Mean weekly wage rate in 2008 http://workforcewv.org/lmi/EW
2008/default.htm 
Used to calculate the 
instate and out of 
state forgone wage 
for the travel expense 




The Consumer Price Index 
compiled by Bureau of Labor 
Statistics and it is based on 1982 





Used to calculate the 
medical expense of 
year 2008 from 2010 
 
Population of WV 
in 2008 
The population of WV in July 






To calculate the 
weighted death age 
for each cancer type 





NAME OF THE 
VARIABLE 
 
DESCRIPTION SOURCE OF DATA 
LIST OF MAIN 
AREAS WHERE THE 
DATA IS USED 
Age adjusted US 
mortality rates 
US mortality age adjusted rates 
by age groups by cancer types 
for all races for 2008 from 






To calculate the 
weighted death age 
for each cancer type 




Net Costs of Care 
by Age, Gender 
and Phase of Care 
(Per Patient). 
Costs in 2010 US 
Dollars 
 
Average Annual Costs of Cancer 
Care in US 2010 Dollars by 
cancer types by phases of 
care: Initial year after 
diagnosis, Last year of life, and 
the period between (Continuing). 
Months of survival are first 
applied to last year of life, any 






Used to calculate the 
total medical expense 
for each cancer types 
for the year 2010 and 
then convert it into 
expenses for year 
2008  
Cancer cases of 
WV in 2008 
The total number of cases of 






Used to calculate the 
total medical expense 
and total forgone 
wage for all cancer 
types in 2008. Also 
used to calculate the 
weighted age of 
diagnosis for each 
cancer type by age 
groups 
 
Diagnosed rate  The diagnosis rate for each 
cancer type by age group 
West Virginia Cancer Registry 





Used to calculate the 
weighted age of 
diagnosis for each 
cancer. 
 
Rate of diagnosis 
by stage  
The percentage of diagnosis in 
each stage of colon cancer  
West Virginia Cancer Registry 
2011 Annual Report 
Cancer Incidence in West 
Virginia, 1993-2008 
 
Used to calculate the 
medical expenses by 
stages for colon 




U.S. Census Bureau Population Projections for 2011 
(or latest available year). 
Used to estimate the 
population the relative 
size of the population 




 Travel costs   
1. Out-of-state travel cost for each county is the sum of round-trip mileage costs, lodging cost, 
and foregone wage costs.   
a. Mileage cost = number of out of state patients times shortest distance in miles to the 
nearest out-of-state hospital × the medical and moving reimbursement rate for mileage at 
the IRS (2008). It has been assumed that a patient will have 9 trips. So this mileage cost 
is further multiplied by 9 trips to the hospital to get the total mileage cost. 
b. Lodging cost = number of out of state patients ×one night at the GSA reimbursement rate 
(2008) ×9 trips.   
c. Forgone wage is represented as the number of out of state patients’ × two days for two 
individuals (patient and companion) at the mean county wage rate for one day (2008) × 9 
trips.  The mean county wage rate for one day was calculated from the average weekly 
wage data. 
2. In-state travel cost for each county is the 
∑                                           . 
a. Mileage cost = the number of instate patients’  fifty miles times the medical and moving 
reimbursement rate for mileage at the IRS (2008)   9 trips.  
b. There is no lodging cost for the instate patients. 
c. Forgone wage = number of in state patients’ × one day for two individuals (patient and 
companion) at the mean county wage rate for one day (2008) × 9 trips.   
 
3. Cost of out-of-state treatment is the difference between mean in-state and out-of-state travel 
expenses times the number of out-of-state cases:                           
                                          
a.                                                                            
                =∑                                                  , where n=55 (counties) 
b.                                                      
                =  ∑                                                , where n=55 (counties) 
c.                                                        , where 0.062 is 
the mean energy Consumer Price Index growth for 2008-2011. 
 




1. Total medical cost is calculated as [Initial average cost + (Continuing age -1)*Continuing 
average cost + (Cancer death average cost- Other death average cost)] 
a) The continuing age is calculated as the difference between the weighted age of death and 
weighted age of diagnosis for each cancer types.  
1. The weighted age of diagnosis is represented in few steps based on eighteen age 
groups and corresponding diagnosed rates for cancer type X. 
a.  A= 
(         
    
     
                 )  
                               
b. B=
 
     
                         
c. C= the middle age for each age group 
d. D= weighted age of diagnosis for each age group=     
e. E= ∑ D to get the weighted age of diagnosis for cancer type X 
2.  The weighted age of death is based on five age groups and corresponding 
mortality rate for cancer site X. 
a. A=            (                   
    
      
) 
b. B=Total no of death cases for cancer X= ∑A  




d. D= the middle age for each age group 
e. E= weighted age of death for each age group=     
f. F=∑E to get the weighted age of death for cancer type X 
2. The initial average, continuing average, cancer death average cost and other death average 
cost are calculated by taking the average of female and male cost for 2010 dollars. 
3. The 2010 medical expense for each cancer type X is then converted to medical expense 2008 
dollars = (                                          ) 
4.  Medical Expense for Out-of-state patients 
a)                   
                                                                        
b)       
                                 
                                                    
 
c)                                                       , where 0.0733 is 
the mean medical expense growth rates.  
 
 Calculations for Continuing Cases (patients beyond the initial year of treatment) 
1. Continuing travel cost (CTC):      
                    (       
          
   
)
   
 
2. Continuing medical expense (CME):  
b)                                 (
          
   
)                 
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c)            =
                                                      
                            
 
d)       
                                              
                                   
 
=
∑ (                                                   )    
                                   
, n=8 
 
∑ (                                                                     )    
                                   
 
 
 Medical Impacts from Out of State Patients Drawn to West Virginia by the Trial Network 
 
1. Medical impacts for out-of-state residents are estimated as the number of patients expected 
from border counties times the mean medical expense per patient. 
a) TPOS (Trial Patients from Other States)*CPP (Cost per Patient) 
b) CPP = ME/Number of Patients 
c) TPOS = BCP (Border Cancer Patients) * 5.8 (trial participation rate) 
d) BCP = Border Population * Cancer Rate * Out-of-state Treatment Rate 





Appendix B: List of Border Counties 
County State Population 
Boyd KY 49,466 
Lawrence KY 16,035 
Martin KY 12,751 
Pike KY 64,904 
Allegany MD 74,692 
Garrett MD 30,051 
Washington MD 148,203 
Athens OH 63,026 
Belmont OH 68,066 
Columbiana OH 107,722 
Gallia OH 30,694 
Jefferson OH 67,691 
Lawrence OH 62,744 
Meigs OH 22,838 
Monroe OH 14,058 
Washington OH 61,048 
Beaver PA 171,673 
Fayette PA 142,605 
Green PA 39,245 
Washington PA 207,389 
Alleghany VA 16,242 
Augusta VA 72,020 
Bath VA 4,482 
Bland VA 6,791 
Buchanan VA 22,860 
Clarke VA 14,588 
Craig VA 4,969 
Frederick VA 74,972 
Giles VA 17,358 
Highland VA 2,338 
Loudon VA 301,171 
Rockingham VA 75,134 
Shenandoah VA 41,036 
Tazewell VA 44,907 
Total   2,153,769 
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Appendix C: Economic Impact Definitions 
Business Volume:  
Sales plus net increase in finished inventories and the value of intra-corporate shipments. 
Equals output (see below) plus the cost of goods sold in retail and wholesale trade. 
Employment:  
The number of jobs in a business, industry, or region. Also, the number of jobs 
attributable to an impact (see below). This is a measure of the number of full-time and 
part-time positions, not necessarily the number of employed persons. Jobs are annual 
average by place of work. A job year is equivalent to one job for one year. 
Employee Compensation:  
 Wages and salaries plus employers' contribution for social insurance (social security, 
unemployment insurance, workers compensation, etc.) and other labor income (pension 
contributions, health benefits, etc.). By place of work unless otherwise stated. 
Impacts:  
 The results of the recirculation of funds throughout a regional economy due to the 
activity of a business, industry, or institution. Estimated by tracing back the flow of 
money through the initial businesses' employees and suppliers, the businesses selling to 
the employees and suppliers, and so on. Thus, they are a way to examine the distribution 
of industries and resources covered in the costs of the initial activity. 
Output:  
 For most sectors, measured as sales plus net inventories and the value of intra-corporate 
shipments. For retail and wholesale trade, measured as gross margins (i.e. sales minus 
cost of goods sold, also equal to the mark-up on goods sold). 
Value Added  
A measure of the value created by a business or industry or attributable to an impact (see 
above). Equal to the value of production minus the cost of purchased goods and services. 
Also equal to employee compensation plus capital income (profits, interest paid, 
depreciation charges), and indirect business taxes (e.g. severance, excise). Corresponds to 
the aggregate concepts of gross domestic product (GDP). 
